Back to the Future: Revisiting Parathyroid Hormone and Calcitonin Control of Bone Remodeling
Authors:
- F. J. A. de PaulaFPF. J. A. de Paula
- C. J. RosenCRC. J. Rosen
- 9 March 2010
- journal article
- review article
- Published by Georg Thieme Verlag KG in Hormone and Metabolic Research
- Vol. 42 (05) , 299-306
Abstract
This review reflects on the past, present, and future of translational research on calcitropic hormones and bone metabolism. Calcitonin (CT) and parathormone (PTH) are complementary hormones involved in the acquisition and maintenance of bone mass and regulation of calcium metabolism. Early research demonstrated that these hormones could have an important role in the treatment of osteoporosis. Calcitonin was approved for this indication by the FDA more than two decades ago, and PTH gained regulatory approval for the treatment of osteoporosis nearly ten years ago. Unfortunately, basic research underlying the mechanism of action of these agents has lagged behind drug approval, and the role of these hormones in bone remodeling is still not firmly established. Moreover, research in bone biology shifted from these hormones to smaller molecules and paracrine regulators of skeletal remodeling. Although important, this development was somewhat unfortunate because without a clearer understanding of how calcitropic hormones work, we cannot be sure that they are being used optimally in the management of osteoporosis. In this review, we look at what is known about CT and PTH and the cells that they target, namely osteoblasts, osteoclasts, and osteocytes. We then identify gaps in knowledge and the research needed to fill them. The conduct of mechanistic studies may point to important factors, such as diurnal variation and dose responsiveness that would lead to improved treatment regimens. By reopening lines of basic and clinical investigation and applying those findings at the bedside, we hope to restart the cycle of translational research in this area.Keywords
This publication has 44 references indexed in Scilit:
- Glucocorticoids in osteonecrosis of the femoral head: A new understanding of the mechanisms of actionThe Journal of Steroid Biochemistry and Molecular Biology, 2009
- Parathyroid hormone secretion in women in late menopause submitted to EDTA-induced hypocalcemiaMaturitas, 2008
- Vitamin D and aging: old concepts and new insightsThe Journal of Nutritional Biochemistry, 2007
- Low prevalence of vitamin D deficiency among adolescents with anorexia nervosaOsteoporosis International, 2007
- Molecular and cellular mechanisms of the anabolic effect of intermittent PTHBone, 2007
- Changes in Osteoblast, Chondrocyte, and Adipocyte Lineages Mediate the Bone Anabolic Actions of PTH and Small Molecule GSK‐3 InhibitorJournal of Cellular Biochemistry, 2007
- Intermittent treatment with parathyroid hormone (PTH) as well as a non-peptide small molecule agonist of the PTH1 receptor inhibits adipocyte differentiation in human bone marrow stromal cellsBone, 2006
- Hypercalcemia in rheumatoid arthritis: relationship with disease activity and bone metabolismRheumatology International, 2006
- SOST is a target gene for PTH in boneBone, 2005
- Insulin-like growth factor I and bone mineral density: experience from animal models and human observational studiesBest Practice & Research Clinical Endocrinology & Metabolism, 2004